Literature DB >> 17939893

Zoster-associated pain: what is known, who is at risk and how can it be managed?

Robert W Johnson1.   

Abstract

Herpes zoster episodes commence with a prodromal period of about 4 days with symptoms including pain and malaise. This is followed by a rash lasting approximately 2-4 weeks, with possible subacute herpetic neuralgia for up to 3 months, followed, in some patients, by a period of post-herpetic neuralgia (PHN) lasting months or possibly years. Severe acute pain is more likely in older females and those with a prodrome or severe rash. Two separate mechanisms of PHN have been proposed: the first is that the excitability of primary afferent neurons is increased after nerve damage, causing irritable nociceptors and central sensitization, resulting in pain and allodynia; the second involves the degeneration of nociceptive neurons, which leads to deafferentation with central hyperactivity, causing pain but without allodynia. Both mechanisms may co-exist in an individual patient. Treatments for acute herpes zoster and PHN include established antivirals, alone or in combination with steroids, analgesics and neural blockade with local anaesthetics. Commonly used pain relief includes acetaminophen/paracetamol, non-steroidal anti-inflammatory drugs (NSAIDs), opioid analgesics, tricyclic antidepressants, gabapentin, pregabalin and topical analgesics. Effective and long-lasting pain relief in herpes zoster and PHN remains a largely unmet medical need.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17939893

Source DB:  PubMed          Journal:  Herpes        ISSN: 0969-7667


  16 in total

Review 1.  Herpes zoster epidemiology, management, and disease and economic burden in Europe: a multidisciplinary perspective.

Authors:  Robert W Johnson; Marie-José Alvarez-Pasquin; Marc Bijl; Elisabetta Franco; Jacques Gaillat; João G Clara; Marc Labetoulle; Jean-Pierre Michel; Luigi Naldi; Luis S Sanmarti; Thomas Weinke
Journal:  Ther Adv Vaccines       Date:  2015-07

2.  Dysregulated Glycoprotein B-Mediated Cell-Cell Fusion Disrupts Varicella-Zoster Virus and Host Gene Transcription during Infection.

Authors:  Stefan L Oliver; Edward Yang; Ann M Arvin
Journal:  J Virol       Date:  2016-12-16       Impact factor: 5.103

3.  Reactivation of herpes zoster along the trigeminal nerve with intractable pain after facial trauma: a case report and literature review.

Authors:  K-C Lin; Che-Chuan Wang; Kai-Yuan Wang; Yi-Chen Liao; Jinn-Rung Kuo
Journal:  BMJ Case Rep       Date:  2009-04-28

Review 4.  Pain in the Elderly.

Authors:  Mark R Jones; Ken P Ehrhardt; Juan G Ripoll; Bharat Sharma; Ira W Padnos; Rachel J Kaye; Alan D Kaye
Journal:  Curr Pain Headache Rep       Date:  2016-04

Review 5.  Reducing the burden of Herpes Zoster in Italy.

Authors:  Giovanni Gabutti; Elisabetta Franco; Paolo Bonanni; Michele Conversano; Antonio Ferro; Marzia Lazzari; Stefania Maggi; Alessandro Rossi; Silvestro Scotti; Francesco Vitale; Antonio Volpi; Donato Greco
Journal:  Hum Vaccin Immunother       Date:  2014-11-01       Impact factor: 3.452

6.  Cost effectiveness of a lidocaine 5% medicated plaster compared with pregabalin for the treatment of postherpetic neuralgia in the UK: a Markov model analysis.

Authors:  Mark Ritchie; Hiltrud Liedgens; Mark Nuijten
Journal:  Clin Drug Investig       Date:  2010       Impact factor: 2.859

7.  The impact of herpes zoster and post-herpetic neuralgia on quality-of-life.

Authors:  Robert W Johnson; Didier Bouhassira; George Kassianos; Alain Leplège; Kenneth E Schmader; Thomas Weinke
Journal:  BMC Med       Date:  2010-06-21       Impact factor: 8.775

8.  Herpes zoster as a sign of AIDS and nonadherence to antiretroviral therapy: a case report.

Authors:  Helena Lucia Barroso dos Reis; Fernanda Sampaio Cavalcante; Katia Regina Netto dos Santos; Mauro Romero Leal Passos; Dennis de Carvalho Ferreira
Journal:  Clinics (Sao Paulo)       Date:  2011       Impact factor: 2.365

Review 9.  Gabapentin for once-daily treatment of post-herpetic neuralgia: a review.

Authors:  Benjamin Beal; Tobias Moeller-Bertram; Jan M Schilling; Mark S Wallace
Journal:  Clin Interv Aging       Date:  2012-07-12       Impact factor: 4.458

Review 10.  Antiepileptics for post-herpetic neuralgia in the elderly: current and future prospects.

Authors:  Gisèle Pickering
Journal:  Drugs Aging       Date:  2014-09       Impact factor: 4.271

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.